Investigational Gene Therapy AVXS-401 Shows Promise in Animal Models of FA

Investigational Gene Therapy AVXS-401 Shows Promise in Animal Models of FA
4.3
(4)

AVXS-401, an experimental gene therapy for Friedreich’s ataxia (FA), is safe, well-tolerated, and leads to clinically meaningful improvements in mice and primate models of the disease, early studies have found.

According to researchers, these promising findings suggest that AVXS-401 is safe for human use and support beginning clinical studies.

Findings were announced in an online presentation, “Efficacy and Safety of CSF- Delivered AVXS-401 in Mice and Non-Human Primates for the Treatment of Friedreich’s Ataxia,” at the virtual 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

FA is caused by an expanded repetition of three nucleotides — the building blocks of DNA — specifically, one guanine (G) and two adenines (A), in the frataxin (FXN) gene.

Such change leads to a significant decrease in the levels of frataxin, a protein involved in iron metabolism and found in mitochondria (the cells’ energy producers). In turn, lack of frataxin leads to the buildup of iron and impairments in energy production that mainly affect high energy-demanding cells, such as those found in the heart and brain.

Previous studies have shown that FA-like symptoms in two mouse models of the disease could be alleviated by forcing cells in the central nervous system (CNS, composed of brain and spinal cord) and heart to produce frataxin.

This was achieved by providing cells with a functional version of the FXN gene delivered by an injection into the animals’ brains (intracranial), abdominal cavities (intraperitoneal), or bloodstreams (intravenous).

AVXS-401 — an investigational gene therapy being developed by AveXis, now part of Novartis — is based on the same principle. The therapy uses a harmless adeno-associated virus (AAV) vector, called AAV9, to deliver a functional copy of the FXN gene to restore the production of frataxin in the tissues affected most by FA.

­Early toxicity studies performed in healthy mice have shown that AVXS-401 is safe and well-tolerated.

Subsequent efficacy studies then showed that a single intracerebroventricular (ICV) injection of low dose AVXS-401 improved behavior and reversed gliosis in a mouse model of FA that lacked frataxin in the CNS.

An ICV injection is administered directly to the brain’s ventricles (fluid-filled brain cavities). Gliosis refers to excessive proliferation of glial cells, which support and protect neurons, in response to injury.

In another mouse model that lacked frataxin in the heart, ICV delivery of AVXS-401 restored cardiac function, prolonged median survival by more than  300%, and prevented the onset of cardiomyopathy (heart disease).

When scaled up to therapeutic doses and given to primates, AVXS-401 was safe and well-tolerated, and led to durable expression of the artificial frataxin in the CNS and heart that was still evident six months after treatment.

Also, delivery into the spinal canal showed correlation between AVXS-401 doses in primates and mice in target tissues.

“Together these preclinical data show that AVXS-401 is suitable for first-in-human studies,” the investigators wrote.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 28

José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • frataxin in mice
  • Omaveloxolone
  • IXICO and FA
  • AVXS-401

How useful was this post?

Click on a star to rate it!

Average rating 4.3 / 5. Vote count: 4

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?